GenrAb Completes $5.6 Million Financing to Accelerate Development of its Lead Antibody Therapy (TGM-010) and Expand Pipeline of Neuroprotective Candidates
- TGM-010 is a naturally occurring, fully-human neuroprotective antibody, with demonstrated ability to cross the BBB, internalize specifically into neurons and engage key stress management machinery to reduce neurological disability
- Financing allows GenrAb to emerge from stealth mode and
aggressively push lead therapy into the clinic - Growing pipeline of novel partnerable neurotherapeutic antibodies
Dallas, TX – April 22, 2025 – GenrAb, Inc., a developer of first-in-class neuroprotective therapies, today announced completion of a private placement with aggregate gross proceeds of $5.6 million dollars (the “Seed Financing”). The Company will use the proceeds from this Seed Financing to accelerate the development of its lead candidate, TGM-010, a novel, fully-human, neuroprotective antibody which is the first in a growing pipeline of novel neurotherapeutic antibodies selected for their potential to become high impact medicines.
GenrAb is optimizing the world’s most effective biological therapy creation engine, the human adaptive immune system. Employing proprietary immunogenetic models to search the cerebrospinal fluid (CSF) of patients undergoing active neurological disease, GenrAb has identified novel, neuronally-specific and neuroprotective antibodies. This is evident from GenrAb’s lead antibody therapy, TGM-010, which has repeatedly and independently demonstrated the capability to cross the blood-brain barrier (BBB), internalize specifically into neurons and engage key stress management machinery to reduce disability. This financing enables GenrAb to aggressively advance TGM-010 through IND and towards human clinical studies in 2026.
“We believe GenrAb has an unprecedented opportunity to develop a novel class of antibody therapeutics that protect neurons under stress.” said GenrAb’s Chief Executive Officer Larry Tiffany. “TGM-010 continues to validate our unique approach that unlocks naturally occurring human antibodies involved in reducing neurodegeneration and maintaining neuronal health. This financing is a key milestone in bringing our first-in-class neuroprotective antibody therapies to the clinic. We’re honored that our investment partners enthusiastically share our vision to seismically disrupt the worldwide neurological treatment market that remains significantly underserved given the number of neurodegenerative diseases for which no effective treatments are available.”
GenrAb is an emerging leader in the growing life sciences ecosystem of North Texas, having won multiple awards for its unique approach to treating neurodegeneration. The Company was founded on technology exclusively licensed from the UT Southwestern Medical Center, and is headquartered in BioLabs at Pegasus Park, Dallas.
“Actium is pleased to have led this capital raise during a period of extreme market volatility,” said Jun Il Kwun, Managing Director of the Actium Group. “The strong demand for investment in GenrAb, after deep diligence by our team and others, resulted in a sophisticated and diverse syndicate including Salem Partners, GPG Ventures, Research Bridge Partners and Maytal Capital. This financing is a vote of confidence in the novel biology driving GenrAb’s innovative and disruptive technology, which has the potential to transform the treatment of CNS disorders to the great benefit of society.”
